肺癌中CRABP2的预后作用:一个元分析
Guang Yang1, Qifan Yin2, Wenhao Wang1
1Department of Thoracic Surgery, The First Hospital of Hebei Medical University, No. 89 Donggang Street, Yuhua District, Shijiazhuang, 050031, Hebei Province, People's Republic of China.
Journal of cardiothoracic surgery
|June 24, 2024
概括
细胞视网膜酸结合蛋白2 (CRABP2) 的血水平增加与肺癌患者的整体存活率 (OS) 较差相关. 这表明CRABP2可能表明瘤的攻击性,并需要进一步研究作为预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物标志物研究 生物标志物研究
背景情况:
- 细胞视网膜酸结合蛋白2 (CRABP2) 在肺癌的预后意义尚未得到充分确立.
- 现有研究需要对CRABP2和患者生存结果之间的关联进行全面评估.
研究的目的:
- 进行一项元分析,评估CRABP2水平与肺癌患者的存活率之间的关系.
- 为了确定CRABP2是否作为肺癌的预后生物标志物.
主要方法:
- 在多个数据库 (Cochrane Library,Ovid,Embase,PubMed,CNKI,Web of Science) 进行了系统的文献搜索,截至2023年5月1日.
- 作为结果指标,提取了危险比率 (HR) 和95%置信区间 (CI).
- 数据分析使用Stata 12.0软件进行.
主要成果:
- 在分析中包括了四项研究.
- 在肺癌患者中,血CRABP2水平升高与整体存活率 (OS) 降低有关 (组合HR:1.14,95%CI:1.00-1.30).
- 血CRABP2水平和无进展生存期 (PFS) (组合HR:1.15,95%CI:0.63-2.09) 之间没有发现显著的关联.
结论:
- 血CRABP2水平的升高与非小细胞肺癌 (NSCLC) 患者的生存状况不佳独立相关.
- 血CRABP2可能反映瘤的生物攻击性.
- 血CRABP2显示出作为NSCLC新型预后生物标志物的潜力,值得进一步研究.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.3K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:21Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342